首页 > 市场调查报告书 > 製药

非专利药生技仿製药

市场调查报告书

商品编码

1738602

2026 年至 2032 年 G-CSF 生物相似药销售市场（按类型、应用、分销管道和地区）

G-CSF Biosimilars Sales Market Size By Type (Short-acting, Long-acting), Application (Oncology, Blood Disorders, Chronic Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Region For 2026-2032

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

G-CSF生物相似药销售市场－2026年至2032年

由于参考生技药品专利到期、癌症发病率上升以及对经济有效治疗方案的需求不断增长，G-CSF 生物相似药市场正经历强劲增长。有利的法规结构、不断完善的医疗基础设施以及国内和已开发市场对生物相似药的日益普及，进一步推动了这一发展。预计这将推动市场规模在 2024 年突破 118.6 亿美元，到 2032 年达到 220.3 亿美元。

除了这些成长要素外，市场还见证了研发投入的增加，以改善製造流程和产品开发。人们越来越关注改善患者获得可负担生物疗法的管道，以及医疗保健提供者对生物相似药的接受度不断提高，这为市场扩张铺平了新的途径。此外，全球医疗保健系统日益重视基于以金额为准的医疗保健和成本控制策略，也推动了各地区市场的成长。生物相似药需求的不断增长将推动市场在2026年至2032年间以8.88%的复合年增长率成长。

全球 G-CSF 生物相似药销售市场定义/概述

G-CSF生物相似药是与用于刺激化疗或严重嗜中性白血球低下症患者白血球生成的参考颗粒细胞增生因子高度相似的化疗製品。这些生物相似生技药品已通过全面的比较测试，证明其品质、安全性和有效性与参考产品相当。

G-CSF生物相似药的开发和生产需要先进的生物技术製程和严格的品管。每种产品都经过广泛的特性鑑定和临床测试，以确保与参考产品具有治疗等效性，同时为医疗保健系统和患者提供成本优势。

G-CSF生物相似药市场前景光明，新技术和新应用具有成长潜力。随着生产流程的进步、跨地区监管协调的加强以及新型给药系统的开发，预计将出现新的发展。适应症的潜在扩展以及对个人化医疗的日益关注，有望带来更加多样化和高效的市场供应。

日益加重的癌症负担将如何推动 G-CSF 生物相似药销售市场的成长？

全球癌症发生率的上升正显着推动G-CSF生物相似药市场的成长。随着全球癌症发生率持续上升，对支持性护理治疗的需求激增，包括用于治疗化疗嗜中性白血球低下症的G-CSF製剂。这一领域对于改善患者预后和促进最佳化疗给药方案至关重要。具有成本效益的生物相似药製剂的出现，使更多患者，尤其是在医疗资源有限的地区，更容易获得这些重要的治疗方法。此外，生物相似药开发和製造流程的进步在保持成本优势的同时提高了产品质量，从而增强了市场吸引力。医疗保健专业人员对生物相似药有效性和安全性的认识不断提高，也推动了市场的扩张。因此，由于癌症患者数量的增加、对有效支持性护理的需求以及医疗保健界生物类似药技术和教育的持续改进等多种因素的共同作用，G-CSF生物相似药市场正在经历强劲增长。

复杂製造流程的挑战如何影响 G-CSF 生物相似药市场的成长？

生产流程的复杂性是G-CSF生物相似药市场成长面临的重大挑战。生产生质类似药需要先进的设备、先进的技术、熟练的人力和大量的投资。此外，保持不同生产批次的产品品质一致性并满足监管标准对製造商而言是一项持续的挑战。对于进入市场的中小型企业来说，这种情况尤其具有挑战性，因为它们经常会遇到资源限制和技术障碍，从而限制其产能。此外，对产品品质和监管合规性的日益关注也增加了生产的复杂性和成本。为了应对这些挑战，该行业正在投资先进的生产技术和製程优化，以提高效率并降低生产成本，同时维持产品品质。这些努力旨在创造一个更永续的生产环境，使现有和新参与企业都能在竞争激烈的G-CSF生物相似药市场中蓬勃发展，同时确保有需要的患者能够获得高品质的治疗。

The G-CSF Biosimilars Sales Market is experiencing robust growth driven by patent expirations of reference biologics, increasing cancer incidence rates, and growing demand for cost-effective treatment options. The market expansion is further supported by favorable regulatory frameworks, improving healthcare infrastructure, and rising adoption of biosimilars in both developed and emerging markets. This is likely to enable the market size to surpass USD 11.86 Billion valued in 2024 to reach a valuation of around USD 22.03 Billion by 2032.

In addition to these growth factors, the market is witnessing increased investment in research and development for enhanced manufacturing processes and product development. The focus on improving patient access to affordable biological treatments and the rising acceptance of biosimilars among healthcare providers is opening new avenues for market expansion. Moreover, the growing emphasis on value-based healthcare and cost containment strategies by healthcare systems worldwide is driving regional market growth. The rising demand for biosimilars is enabling the market to grow at a CAGR of 8.88% from 2026 to 2032.

Global G-CSF Biosimilars Sales Market: Definition/Overview

G-CSF biosimilars are biologic medical products that are highly similar to reference granulocyte colony-stimulating factors used to stimulate the production of white blood cells in patients undergoing chemotherapy or those with severe neutropenia. These biosimilars have demonstrated comparable quality, safety, and efficacy to their reference products through comprehensive comparative studies.

The development and manufacturing of G-CSF biosimilars involve sophisticated biotechnology processes and stringent quality controls. Each product undergoes extensive characterization and clinical testing to ensure therapeutic equivalence to the reference product while offering cost advantages to healthcare systems and patients.

The future scope of the G-CSF biosimilars market is promising, with potential for growth in emerging technologies and applications. Advancements in manufacturing processes, increasing regulatory harmonization across regions, and the development of novel drug delivery systems are expected to open new market opportunities. The potential for expanding indications and the growing focus on personalized medicine may lead to more diverse and effective market offerings.

How does the Increasing Cancer Burden Drive the Growth of The G-CSF Biosimilars Market?

The rising global cancer burden significantly drives growth in the G-CSF Biosimilars Market. As cancer incidence rates continue to escalate worldwide, the demand for supportive care treatments, including G-CSF products for managing chemotherapy-induced neutropenia, has surged. This segment is crucial for improving patient outcomes and facilitating optimal chemotherapy dosing schedules. The availability of cost-effective biosimilar alternatives has made these essential treatments more accessible to a broader patient population, especially in regions with limited healthcare resources. Furthermore, advancements in biosimilar development and manufacturing processes have improved product quality while retaining cost advantages, contributing to their attractiveness in the market. The increasing awareness among healthcare providers regarding the efficacy and safety of biosimilars is also fostering market expansion. As a result, the G-CSF biosimilars market is witnessing robust growth, driven by a combination of factors such as rising cancer cases, the need for effective supportive care, and continuous improvements in biosimilar technology and education within the healthcare community.

How is the Challenge of Complex Manufacturing Processes Impacting the Growth of The G-CSF Biosimilars Market?

The complexity of manufacturing processes poses a significant challenge impacting the growth of the G-CSF Biosimilars Market. Producing biosimilars necessitates sophisticated facilities, advanced technology, and highly skilled personnel, leading to substantial investment requirements. Additionally, maintaining consistent product quality and meeting regulatory standards across different manufacturing batches presents ongoing challenges for manufacturers. This situation is particularly difficult for smaller companies entering the market, as they often encounter resource constraints and technical hurdles that limit their capabilities. Furthermore, the increasing emphasis on product quality and regulatory compliance adds to the complexities and costs of manufacturing. To address these challenges, the industry is investing in advanced manufacturing technologies and process optimization, which can enhance efficiency and reduce production costs while maintaining product quality. These initiatives aim to create a more sustainable production environment, enabling both established and new players to thrive in the competitive landscape of the G-CSF biosimilars market while ensuring access to high-quality treatments for patients in need.

Category-wise Acumens

How will the Dominance of Long-acting G-CSF Drive the Growth of the Type Segment?

Long-acting G-CSF's dominance in the Type segment is significantly driving growth in the overall biosimilars market. The improved patient compliance, reduced administration frequency, and enhanced therapeutic outcomes associated with long-acting formulations position them as the preferred choice among healthcare providers and patients. These formulations benefit from established clinical evidence and widespread acceptance in various treatment protocols, reinforcing their market presence.

Continued innovation in drug delivery systems and improved pharmacokinetic profiles further fuels the market leadership of long-acting G-CSF. The development of new formulations and administration devices has successfully expanded the patient base and improved treatment adherence. Additionally, the convenience of administration and fewer hospital visits contribute to its success, particularly in ambulatory care settings. As manufacturing technology advances and patient preferences evolve, the long-acting segment is expected to maintain its growth momentum through ongoing product innovation and strategic market expansion. This focus on enhancing patient experience and treatment outcomes will be pivotal in sustaining the long-acting G-CSF segment's leadership in the biosimilars market.

How will the Growing Importance of Hospital Pharmacies Drive the Expansion of The Distribution Channel Segment?

The dominance of hospital pharmacies in G-CSF biosimilar distribution highlights the critical role of institutional healthcare providers in managing complex biological treatments. Hospital pharmacies are equipped with specialized storage facilities, trained personnel, and integrated care coordination essential for handling biological products. This capability is particularly vital for maintaining product integrity and ensuring proper administration.

Additionally, hospital pharmacies enable direct interaction between healthcare providers and patients, allowing for better monitoring and management of treatment outcomes. Their ability to provide comprehensive patient care while adhering to cold chain requirements makes hospital pharmacies an ideal distribution channel for G-CSF biosimilars. Consequently, we can anticipate increased investment in hospital pharmacy infrastructure and staff training to improve the efficiency of biological product handling. Innovations in inventory management systems and patient care coordination within the hospital pharmacy segment will facilitate more effective distribution and utilization of G-CSF biosimilars. This focus on enhancing hospital pharmacy capabilities is essential for ensuring that patients receive high-quality care and access to necessary treatments

Country/Region-wise Acumens

Will the Advanced Healthcare Infrastructure Drive the Dominance of North America in The G-CSF Biosimilars Market?

The dominance of North America in the G-CSF biosimilars sales market is significantly driven by its advanced healthcare infrastructure and robust regulatory framework. The region's early adoption of biosimilars, bolstered by favorable reimbursement policies and healthcare cost containment initiatives, has established a strong market foundation. This favorable context is enhanced by high awareness among healthcare providers and patients regarding the benefits of biosimilars. North America's leadership in oncology treatment and supportive care has further solidified its position in the G-CSF biosimilars market. The region's substantial investment in healthcare technology and a strong emphasis on evidence-based medicine have facilitated broader acceptance of biosimilar products. Additionally, the presence of major pharmaceutical companies and research institutions fosters continuous innovation and market growth, ensuring North America remains a key market for G-CSF biosimilar manufacturers and developers. As the market evolves, ongoing collaborations and advancements in biosimilar development are expected to reinforce North America's dominant position in the global G-CSF biosimilars landscape.

Will the Growing Healthcare Access Drive the Expansion of The G-CSF Biosimilars Market in Asia-Pacific?

The rapidly improving healthcare access in the Asia-Pacific region is a key driver of expansion in the G-CSF Biosimilars sales Market, presenting significant growth opportunities. With large patient populations and increasing healthcare investments, countries like China, India, and Japan are witnessing substantial growth in biosimilar adoption. This trend is fueled by government initiatives aimed at improving healthcare accessibility, rising healthcare expenditure, and growing insurance coverage. As healthcare systems expand, the demand for cost-effective biological treatments increases, enhancing opportunities for biosimilar manufacturers. The region's evolving regulatory landscape, where authorities are establishing clearer pathways for biosimilar approval, further propels this growth. Innovations in local manufacturing capabilities, coupled with strategic partnerships between global and regional players, are accelerating market development. This collaborative environment is establishing the Asia-Pacific region as a crucial market for G-CSF biosimilar manufacturers. Furthermore, as awareness of biosimilars grows among healthcare providers and patients, the region is poised for continued expansion in the biosimilars sector, reflecting a shift towards sustainable healthcare solutions.

Competitive Landscape

The G-CSF biosimilars sales market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the G-CSF biosimilars sales market include:

Sandoz (Novartis)

Pfizer Inc.

Teva Pharmaceutical Industries

Amgen Inc.

Reddy's Laboratories

Coherus BioSciences

Biocon

Intas Pharmaceuticals

Mylan N.V. (Now Viatris)

Kashiv BioSciences

Latest Development

1 INTRODUCTION OF GLOBAL G-CSF BIOSIMILARS SALES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL G-CSF BIOSIMILARS SALES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY TYPE

5.1 Overview
5.2 Short-acting G-CSF
5.3 Long-acting G-CSF

6 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY APPLICATION

6.1 Overview
6.2 Blood Disorders
6.3 Oncology Diseases
6.4 Chronic Diseases
6.5 Others (Acute Radiation Syndrome)

7 GLOBAL G-CSF BIOSIMILARS SALES MARKET, DISTRIBUTION CHANNEL

7.1 Overview
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies
7.5 Others (Specialty Clinics)

8 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL G-CSF BIOSIMILARS SALES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sandoz (Novartis)
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Teva Pharmaceutical Industries
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Amgen Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Reddy's Laboratories
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Coherus BioSciences
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Biocon
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Intas Pharmaceuticals
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Mylan N.V. (Now Viatris)
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Kashiv BioSciences
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 AbbVie
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 Appendix

11.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年 G-CSF 生物相似药销售市场（按类型、应用、分销管道和地区）